Document Detail


Spinal Cord Ischemia/Injury.
MedLine Citation:
PMID:  24502574     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Opioids; i.e., compounds with morphine-like actions, and their receptors have been demonstrated to be involved in cardioprotection, at least in scientific studies, which makes sense as cardiomyocytes express most of the known opioid receptors and their agonists. In vitro and in vivo studies have demonstrated that the opioid system plays various important roles in maintaining cardiac function; i.e., it influences cardiac rhythm, cell stress, and even developmental processes. In support of these research findings, there is also good clinical evidence that opioids are effective as cardioprotective drugs. In fact, in the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines for coronary artery bypass graft surgery opioids and volatile halogenated anesthetics are referred to as anti-ischemic or conditioning agents. Although opioids are administered to all patients who undergo surgery as well as patients admitted to the ICU, including those that suffer heart attacks, no recommendations about their use for the preconditioning/management of myocardial ischemia have been included in recent clinical guidelines due to the weak clinical evidence about their effects. Opioids have been used as pain control agents in the clinical setting for a long time. As such, surgical, critical care, and cancer patients routinely receive them. On the other hand, ischemic heart disease continues to be a leading cause of morbidity and mortality in developed countries, and opioid therapy might be useful for treating the condition. This review examines recent clinical trials of the effects of opioids on ischemic heart disease and discusses the barriers to the use of opioids for cardioprotection.
Authors:
T Ishikawa; H Suzuki; K Ishikawa; S Yasuda; T Matsui; M Yamamoto; T Kakeda; S Yamamoto; Y Owada; T L Yaksh
Related Documents :
24416594 - Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular ...
24429674 - Autocrine and paracrine function of angiotensin 1-7 in tissue repair during hypertension.
23799044 - Contrasting roles of e2f2 and e2f3 in cardiac neovascularization.
24104944 - Improvement of functional recovery of donor heart following cold static storage with do...
487544 - Cross-sectional echocardiography. i. analysis of mathematic models for quantifying mass...
19808544 - Evaluation of coronary atherosclerosis by multislice computed tomography in patients wi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-2-03
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2014-2-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protective Effects of Anesthetics on the Spinal Cord.
Next Document:  Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality.